ProShares Ultra NASDAQ Biotechnology
21 hedge funds and large institutions have $6.5M invested in ProShares Ultra NASDAQ Biotechnology in 2024 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 5 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more capital invested
Capital invested by funds: $ → $
less ownership
Funds ownership: →
less funds holding
Funds holding: →
20% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 5
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
Holders
21
Holding in Top 10
–
Calls
$752K
Puts
$465K
Top Buyers
| 1 | +$703K | |
| 2 | +$255K | |
| 3 | +$23.8K | |
| 4 |
TC
Truvestments Capital
Sarasota,
Florida
|
+$7.97K |
| 5 |
Morgan Stanley
New York
|
+$6.44K |
Top Sellers
| 1 | -$528K | |
| 2 | -$451K | |
| 3 | -$226K | |
| 4 |
CIC
Chase Investment Counsel
Charlottesville,
Virginia
|
-$99K |
| 5 |
TFA
Toth Financial Advisory
Leesburg,
Virginia
|
-$76.6K |